Our journey:
Changing the future of inflammatory diseases and skin health
Our journey:
Changing the future of inflammatory diseases and skin health
Our Story
Our story begins with a team of scientists and visionaries who are committed to addressing the greatest unmet needs in healthcare: inflammatory diseases, skin health.
When we realized the potential of SERPIN proteins to alleviate these inflammatory diseases, skin health, we committed to developing a first-in-class therapy to restore immune balance and fight against the harmful inflammatory environment and skin problems.
Our therapy, now called SP16, is currently in preclinical and clinical trials covering a variety of rare, chronic and acute diseases. We are currently working with leaders in different research fields to bring our technology to patients who need it most.
We believe that Serpin Daisy’s therapeutics are poised to shift the inflammatory disease and skin health landscape, and provide lifelong solutions for a broad patient population.
Management and Board
Management Board
Cohava Gelber, PhD, MBA
Founder, Executive Chairperson, & CEO
Larry Douglas Altstiel, MD, PhD
Acting CMO
David Dove, MD, MBA
Board Member
John H Abeles, MD
Board Member
Guy Yachin, MBA
Board Member
Alexander Fleming, MD
Board Member
Dan Aitkens, CPA
Acting CFO
Scientific Advisory Board
Alexander Fleming, MD
Chair of Scientific Advisory Board
Larry Douglas Altstiel, MD, PhD
Scientific Advisory Board Member
Wendy Campana, PhD
Scientific Advisory Board Member
Antonio Gotto, MD, PhD
Scientific Advisory Board Member
Marc Rothenberg, MD, PhD
Scientific Advisory Board Member
Gordon Smith MD
Scientific Advisory Board Member
Lawrence Steinmann, MD
Scientific Advisory Board Member
Jerome (“Jerry) Zeldis, MD, PhD
Scientific Advisory Board Member
Jonathan Zenilman, MD
Scientific Advisory Board Member
Emanuel Petricoin III, PhD
Scientific Advisory Board Member
Copyright © Serpin Daisy,
LLC 2022 - All Rights Reserved
